Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

blinatumomab 3Cytarabine 3venetoclax 2revumenib 2Daunorubicin 2quizartinib 1obinutuzumab 1nilotinib 1ivosidenib 1etoposide phosphate 1bosutinib 1acalabrutinib 1Mitoxantrone 1Midazolam 1Itraconazole 1Imatinib Mesylate 1Idarubicin 1Gemtuzumab 1Etoposide 1Drug Therapy 1Cobicistat 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Leukemia × Itraconazole × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡